RS61529B9 - Oligonukleotidi za indukovanje ekspresije paternalnog ube3a - Google Patents

Oligonukleotidi za indukovanje ekspresije paternalnog ube3a

Info

Publication number: RS61529B9
Authority: RS; Serbia
Prior art keywords: oligonucleotides; paternal ube3a; ube3a expression; inducing; inducing paternal
Prior art date: 2015-11-12

Application number

RS20210241A

Other languages

English (en)

Inventor

Veronica Costa

Maj Hedtjärn

Marius Hoener

Ravi Jagasia

Mads Aaboe Jensen

Christoph Patsch

Lykke Pedersen

Søren Vestergaard Rasmussen

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-11-12

Filing date

2016-11-11

Publication date

2024-04-30

2016-11-11 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

2021-04-29 Publication of RS61529B1 publication Critical patent/RS61529B1/sr

2024-04-30 Publication of RS61529B9 publication Critical patent/RS61529B9/sr

Links

108091034117 Oligonucleotide Proteins 0.000 title 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title 1
230000001939 inductive effect Effects 0.000 title 1
230000008775 paternal effect Effects 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0018—Culture media for cell or tissue culture
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0619—Neurons
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0623—Stem cells
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5058—Neurological cells
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/34—Allele or polymorphism specific uses
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/38—Vitamins
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/44—Thiols, e.g. mercaptoethanol
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/01—Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/11—Epidermal growth factor [EGF]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/119—Other fibroblast growth factors, e.g. FGF-4, FGF-8, FGF-10
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/13—Nerve growth factor [NGF]; Brain-derived neurotrophic factor [BDNF]; Cilliary neurotrophic factor [CNTF]; Glial-derived neurotrophic factor [GDNF]; Neurotrophins [NT]; Neuregulins
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
- C12N2501/41—Hedgehog proteins; Cyclopamine (inhibitor)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/72—Transferases (EC 2.)
- C12N2501/727—Kinases (EC 2.7.)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2503/00—Use of cells in diagnostics
- C12N2503/02—Drug screening
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/50—Proteins
- C12N2533/52—Fibronectin; Laminin

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Biomedical Technology (AREA)
Chemical & Material Sciences (AREA)
Genetics & Genomics (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Biotechnology (AREA)
General Health & Medical Sciences (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Molecular Biology (AREA)
General Engineering & Computer Science (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biochemistry (AREA)
Microbiology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Physics & Mathematics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Cell Biology (AREA)
Immunology (AREA)
Biophysics (AREA)
Plant Pathology (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Toxicology (AREA)
Food Science & Technology (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Analytical Chemistry (AREA)
Tropical Medicine & Parasitology (AREA)
Developmental Biology & Embryology (AREA)

RS20210241A 2015-11-12 2016-11-11 Oligonukleotidi za indukovanje ekspresije paternalnog ube3a RS61529B9 (sr)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
EP15194367		2015-11-12
EP16189502		2016-09-19
PCT/EP2016/077383 WO2017081223A1 (en)	2015-11-12	2016-11-11	Oligonucleotides for inducing paternal ube3a expression
EP16798440.0A EP3374509B1 (en)	2015-11-12	2016-11-11	Oligonucleotides for inducing paternal ube3a expression

Publications (2)

Publication Number	Publication Date
RS61529B1 RS61529B1 (sr)	2021-04-29
RS61529B9 true RS61529B9 (sr)	2024-04-30

Family

ID=57345910

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
RS20210241A RS61529B9 (sr)	2015-11-12	2016-11-11	Oligonukleotidi za indukovanje ekspresije paternalnog ube3a

Country Status (29)

Country	Link
US (9)	US10494633B2 (sr)
EP (5)	EP3374509B1 (sr)
JP (6)	JP7066609B2 (sr)
KR (3)	KR102185465B1 (sr)
CN (5)	CN108350432A (sr)
AU (4)	AU2016352836B2 (sr)
BR (1)	BR112018007633A2 (sr)
CA (1)	CA3004799C (sr)
CL (3)	CL2018001189A1 (sr)
CO (1)	CO2018004550A2 (sr)
CR (3)	CR20220077A (sr)
DK (1)	DK3374509T3 (sr)
ES (1)	ES2852998T4 (sr)
HK (3)	HK1253325A1 (sr)
HR (1)	HRP20210227T1 (sr)
HU (1)	HUE053197T2 (sr)
IL (3)	IL281211B2 (sr)
LT (1)	LT3374509T (sr)
MX (4)	MX2018004978A (sr)
PE (2)	PE20210451A1 (sr)
PH (1)	PH12018501005A1 (sr)
PL (1)	PL3374509T3 (sr)
RS (1)	RS61529B9 (sr)
RU (1)	RU2742007C2 (sr)
SG (1)	SG11201803951QA (sr)
SI (1)	SI3374509T1 (sr)
UA (1)	UA125963C2 (sr)
WO (3)	WO2017081250A1 (sr)
ZA (1)	ZA201802494B (sr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BRPI0923225A2 (pt)	2008-12-02	2016-10-04	Chiralgen Ltd	metodo para sintese de acidos nucleicos modificados no atomo de fosforo
BR112012000828A8 (pt)	2009-07-06	2017-10-10	Ontorii Inc	Novas pró-drogas de ácido nucleico e métodos de uso das mesmas
WO2012039448A1 (ja)	2010-09-24	2012-03-29	株式会社キラルジェン	不斉補助基
EP3248982A1 (en)	2011-07-19	2017-11-29	Wave Life Sciences Ltd.	Thiosulfonate reagents for the synthesis of functionalized nucleic acids
PT2872485T (pt)	2012-07-13	2021-03-05	Wave Life Sciences Ltd	Grupo auxiliar assimétrico
RU2015104762A (ru)	2012-07-13	2018-08-31	Уэйв Лайф Сайенсес Лтд.	Хиральный контроль
JPWO2015108048A1 (ja)	2014-01-15	2017-03-23	株式会社新日本科学	抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
EP3095461A4 (en)	2014-01-15	2017-08-23	Shin Nippon Biomedical Laboratories, Ltd.	Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
KR20230152178A (ko)	2014-01-16	2023-11-02	웨이브 라이프 사이언시스 리미티드	키랄 디자인
WO2016086104A1 (en)	2014-11-25	2016-06-02	Ionis Pharmaceuticals, Inc.	Modulation of ube3a-ats expression
BR112018007633A2 (pt)	2015-11-12	2018-11-06	F. Hoffmann-La Roche Ag	oligonucleotídeos para indução de expressão de ube3a paterna
AU2018375807A1 (en)	2017-12-01	2020-05-07	The Texas A&M University System	Angelman syndrome antisense treatment
CA3090901A1 (en)	2018-02-12	2019-08-15	Ionis Pharmaceuticals, Inc.	Modified compounds and uses thereof
CN108795935B (zh) *	2018-05-23	2022-06-21	中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心)	日本血吸虫SjELAV-like 1基因的siRNA及其应用
CA3113648A1 (en) *	2018-09-21	2020-03-26	University Of Connecticut	Compositions and methods to restore paternal ube3a gene expression in human angelman syndrome
EP3911957A1 (en) *	2019-01-17	2021-11-24	F. Hoffmann-La Roche AG	E3 ubiquitin ligase (ube3a) protein targets
KR20210144822A (ko)	2019-03-29	2021-11-30	아이오니스 파마수티컬즈, 인코포레이티드	Ube3a-ats를 조절하기 위한 화합물 및 방법
CA3139678A1 (en) *	2019-05-22	2020-11-26	The University Of North Carolina At Chapel Hill	Ube3a genes and expression cassettes and their use
CN113874494A (zh)	2019-05-28	2021-12-31	豪夫迈·罗氏有限公司	产生单核细胞祖细胞的方法
EP4162047A1 (en) *	2020-06-09	2023-04-12	Roche Innovation Center Copenhagen A/S	Guanosine analogues for use in therapeutic polynucleotides
WO2022158487A1 (ja)	2021-01-21	2022-07-28	藤森工業株式会社	積層フィルムおよび包装袋
WO2023217890A1 (en)	2022-05-10	2023-11-16	F. Hoffmann-La Roche Ag	Antisense oligonucleotides targeting cfp-elk1 intergene region

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4373084A (en)	1981-07-07	1983-02-08	E. I. Du Pont De Nemours And Company	Sulfur-modified polypropylene ether glycols, a method for preparing them, and polyurethanes prepared therefrom
DE69233046T2 (de)	1991-10-24	2004-03-04	Isis Pharmaceuticals, Inc., Carlsfeld	Derivatisierte oligonukleotide mit verbessertem aufnahmevermögen
JP3756313B2 (ja)	1997-03-07	2006-03-15	武今西	新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
US6617162B2 (en)	2001-12-18	2003-09-09	Isis Pharmaceuticals, Inc.	Antisense modulation of estrogen receptor alpha expression
EP1557424A1 (en)	1997-09-12	2005-07-27	Exiqon A/S	Bi-cyclic nucleoside, nucleotide and oligonucleoide analogues
US6238921B1 (en)	1998-03-26	2001-05-29	Isis Pharmaceuticals, Inc.	Antisense oligonucleotide modulation of human mdm2 expression
CA2359816C (en) *	1999-01-06	2010-08-03	Genenews Inc.	Method for the detection of gene transcripts in blood and uses thereof
BRPI0008131B8 (pt)	1999-02-12	2021-05-25	Daiichi Sankyo Co Ltd	composto ou um sal deste, análogo de oligonucleotídeo, composição farmacêutica, sonda para um gene,iniciador para começar a amplificação, uso de um análogo de oligonucleotídeo ou de um sal deste farmacologicamente aceitável, agente antisentido, e, agente antígeno
NZ514348A (en)	1999-05-04	2004-05-28	Exiqon As	L-ribo-LNA analogues
US6617442B1 (en)	1999-09-30	2003-09-09	Isis Pharmaceuticals, Inc.	Human Rnase H1 and oligonucleotide compositions thereof
CA2396460A1 (en)	1999-12-02	2001-06-07	Myriad Genetics, Inc.	Protein-protein interactions
US6300132B1 (en)	1999-12-17	2001-10-09	Isis Pharmaceuticals, Inc.	Antisense inhibition of telomeric repeat binding factor 2 expression
AU2001268163A1 (en) *	2000-06-01	2001-12-11	Genaissance Pharmaceuticals, Inc.	Haplotypes of the ube3a gene
US20030087855A1 (en)	2001-09-13	2003-05-08	Isis Pharmaceuticals Inc.	Antisense modulation of protein kinase R expression
EP2270024B1 (en) *	2001-06-21	2018-10-24	Ionis Pharmaceuticals, Inc.	Antisense modulation of superoxide dismutase 1, soluble expression
US20050124572A1 (en) *	2002-06-17	2005-06-09	Freier Susan M.	Compositions and their uses directed to signal tranducers
JP2006507808A (ja)	2002-08-14	2006-03-09	ファルマシア・コーポレーション	Ｎａｖ１．３発現のアンチセンス調節
US20040132063A1 (en) *	2002-09-25	2004-07-08	Gierse James K.	Antisense modulation of microsomal prostaglandin E2 synthase expression
DK1569661T3 (da)	2002-11-18	2010-01-11	Santaris Pharma As	Antisense design
KR20060115351A (ko) *	2003-08-29	2006-11-08	위스콘신 얼럼나이 리서어치 화운데이션	영장류 배아 줄기 세포 기원의 신경 줄기 세포, 운동 뉴런및 도파민 뉴런의 시험관내 분화 방법
WO2007031091A2 (en)	2005-09-15	2007-03-22	Santaris Pharma A/S	Rna antagonist compounds for the modulation of p21 ras expression
CN103301475B (zh)	2005-12-28	2016-08-03	斯克里普斯研究所	药物组合物和表达载体以及调节基因表达的方法和核酸分子的应用
DK1984381T3 (da)	2006-01-27	2010-11-01	Isis Pharmaceuticals Inc	6-modificerede bicycliske nukleinsyreanaloger
WO2007143315A2 (en)	2006-05-05	2007-12-13	Isis Pharmaceutical, Inc.	Compounds and methods for modulating expression of pcsk9
US7666854B2 (en)	2006-05-11	2010-02-23	Isis Pharmaceuticals, Inc.	Bis-modified bicyclic nucleic acid analogs
CA2651453C (en)	2006-05-11	2014-10-14	Isis Pharmaceuticals, Inc.	5'-modified bicyclic nucleic acid analogs
WO2008113832A2 (en)	2007-03-22	2008-09-25	Santaris Pharma A/S	SHORT RNA ANTAGONIST COMPOUNDS FOR THE MODULATION OF TARGET mRNA
PE20090064A1 (es)	2007-03-26	2009-03-02	Novartis Ag	Acido ribonucleico de doble cadena para inhibir la expresion del gen e6ap humano y composicion farmaceutica que lo comprende
US8278425B2 (en)	2007-05-30	2012-10-02	Isis Pharmaceuticals, Inc.	N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
DK2173760T4 (en)	2007-06-08	2016-02-08	Isis Pharmaceuticals Inc	Carbocyclic bicyclic nukleinsyreanaloge
US8278283B2 (en)	2007-07-05	2012-10-02	Isis Pharmaceuticals, Inc.	6-disubstituted or unsaturated bicyclic nucleic acid analogs
US8546556B2 (en)	2007-11-21	2013-10-01	Isis Pharmaceuticals, Inc	Carbocyclic alpha-L-bicyclic nucleic acid analogs
WO2009090182A1 (en)	2008-01-14	2009-07-23	Santaris Pharma A/S	C4'-substituted - dna nucleotide gapmer oligonucleotides
DK2285819T3 (da)	2008-04-04	2013-12-02	Isis Pharmaceuticals Inc	Oligomere forbindelser omfattende neutralt bundne, terminale bicykliske nukleosider
US8501805B2 (en)	2008-09-24	2013-08-06	Isis Pharmaceuticals, Inc.	Substituted alpha-L-bicyclic nucleosides
US8642334B2 (en) *	2009-02-17	2014-02-04	Memorial Sloan Kettering Cancer Center	Methods of neural conversion of human embryonic stem cells
EP2462153B1 (en)	2009-08-06	2015-07-29	Isis Pharmaceuticals, Inc.	Bicyclic cyclohexose nucleic acid analogs
CN102762718B (zh) *	2009-10-13	2015-06-17	干细胞技术公司	用于分化干细胞的重量克分子渗透压浓度控制
RU2609631C2 (ru)	2009-12-23	2017-02-02	Курна, Инк.	Лечение заболеваний, связанных с фактором роста гепатоцитов (фрг), посредством ингибирования природного антисмыслового транскрипта к фрг
US8846637B2 (en)	2010-06-08	2014-09-30	Isis Pharmaceuticals, Inc.	Substituted 2′-amino and 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
RU2611190C2 (ru)	2010-07-14	2017-02-21	Курна, Инк.	Лечение заболеваний, связанных с геном dlg, путем ингибирования природного антисмыслового транскрипта гена dlg
CN106434648A (zh)	2010-07-19	2017-02-22	F·C·贝内特	肌强直性营养障碍蛋白激酶(dmpk)表达的调节
MX348419B (es) *	2010-08-19	2017-06-12	F Hoffmann-La Roche Ag *	Conversion de celulas somaticas a celulas madre, neurales reprogramadas, inducidas (irnscs).
US9714427B2 (en)	2010-11-11	2017-07-25	The University Of North Carolina At Chapel Hill	Methods and compositions for unsilencing imprinted genes
WO2012068405A2 (en)	2010-11-17	2012-05-24	Isis Pharmaceuticals, Inc.	Modulation of alpha synuclein expression
WO2012135621A2 (en) *	2011-03-30	2012-10-04	Cellular Dynamics International. Inc	Priming of pluripotent stem cells for neural differentiation
CN103502273A (zh)	2011-04-20	2014-01-08	罗氏格黎卡特股份公司	用于pH依赖性通过血脑屏障的方法和构建体
WO2013033230A1 (en)	2011-08-29	2013-03-07	Isis Pharmaceuticals, Inc.	Oligomer-conjugate complexes and their use
SG11201401314PA (en)	2011-09-07	2014-09-26	Marina Biotech Inc	Synthesis and uses of nucleic acid compounds with conformationally restricted monomers
US9221864B2 (en)	2012-04-09	2015-12-29	Isis Pharmaceuticals, Inc.	Tricyclic nucleic acid analogs
DK3461895T3 (da) *	2012-06-25	2020-07-20	Ionis Pharmaceuticals Inc	Modulation af ube3a-ats-ekspression
KR102112892B1 (ko)	2012-11-15	2020-05-19	로슈 이노베이션 센터 코펜하겐 에이/에스	올리고뉴클레오티드 콘쥬게이트
WO2014077693A1 (en)	2012-11-16	2014-05-22	Academisch Ziekenhuis Leiden H.O.D.N. Lumc	Means and methods for reducing an effect of aging in a mammalian cell
ES2939807T3 (es) *	2014-03-21	2023-04-27	Fujifilm Cellular Dynamics Inc	Producción de neuronas dopaminérgicas del mesencéfalo y métodos para su utilización
BR112018007633A2 (pt)	2015-11-12	2018-11-06	F. Hoffmann-La Roche Ag	oligonucleotídeos para indução de expressão de ube3a paterna
BR112019027692A2 (pt)	2017-06-28	2020-11-24	University Of South Florida	gene ube3a modificado para uma abordagem terapêutica genética para a síndrome de angelman
AU2018375807A1 (en)	2017-12-01	2020-05-07	The Texas A&M University System	Angelman syndrome antisense treatment
JP7383618B2 (ja)	2018-01-26	2023-11-20	エフ．ホフマン－ラロシュアーゲー	放射標識オリゴヌクレオチドおよびその調製のための方法
KR20210144822A (ko)	2019-03-29	2021-11-30	아이오니스 파마수티컬즈, 인코포레이티드	Ube3a-ats를 조절하기 위한 화합물 및 방법

2016
- 2016-11-11 BR BR112018007633-3A patent/BR112018007633A2/pt active Search and Examination
- 2016-11-11 KR KR1020187013292A patent/KR102185465B1/ko active IP Right Grant
- 2016-11-11 CR CR20220077A patent/CR20220077A/es unknown
- 2016-11-11 SI SI201631093T patent/SI3374509T1/sl unknown
- 2016-11-11 ES ES16798440T patent/ES2852998T4/es active Active
- 2016-11-11 CN CN201680066009.XA patent/CN108350432A/zh active Pending
- 2016-11-11 WO PCT/EP2016/077429 patent/WO2017081250A1/en active Application Filing
- 2016-11-11 LT LTEP16798440.0T patent/LT3374509T/lt unknown
- 2016-11-11 RU RU2018119315A patent/RU2742007C2/ru active
- 2016-11-11 PE PE2020000810A patent/PE20210451A1/es unknown
- 2016-11-11 DK DK16798440.0T patent/DK3374509T3/da active
- 2016-11-11 EP EP16798440.0A patent/EP3374509B1/en active Active
- 2016-11-11 CN CN202211275954.4A patent/CN116064539A/zh active Pending
- 2016-11-11 WO PCT/EP2016/077435 patent/WO2017081254A1/en active Application Filing
- 2016-11-11 SG SG11201803951QA patent/SG11201803951QA/en unknown
- 2016-11-11 PE PE2018000752A patent/PE20181157A1/es unknown
- 2016-11-11 HU HUE16798440A patent/HUE053197T2/hu unknown
- 2016-11-11 CN CN202211275978.XA patent/CN116064540A/zh active Pending
- 2016-11-11 CR CR20200118A patent/CR20200118A/es unknown
- 2016-11-11 CN CN201680065987.2A patent/CN108350431A/zh active Pending
- 2016-11-11 IL IL281211A patent/IL281211B2/en unknown
- 2016-11-11 PL PL16798440T patent/PL3374509T3/pl unknown
- 2016-11-11 UA UAA201806476A patent/UA125963C2/uk unknown
- 2016-11-11 IL IL300119A patent/IL300119A/en unknown
- 2016-11-11 RS RS20210241A patent/RS61529B9/sr unknown
- 2016-11-11 AU AU2016352836A patent/AU2016352836B2/en active Active
- 2016-11-11 KR KR1020207033999A patent/KR102482440B1/ko not_active Application Discontinuation
- 2016-11-11 EP EP16798672.8A patent/EP3374499A1/en active Pending
- 2016-11-11 EP EP20204481.4A patent/EP3798307A1/en active Pending
- 2016-11-11 KR KR1020227045154A patent/KR20230008233A/ko not_active Application Discontinuation
- 2016-11-11 JP JP2018521433A patent/JP7066609B2/ja active Active
- 2016-11-11 CA CA3004799A patent/CA3004799C/en active Active
- 2016-11-11 WO PCT/EP2016/077383 patent/WO2017081223A1/en active Application Filing
- 2016-11-11 JP JP2018524194A patent/JP6751142B2/ja active Active
- 2016-11-11 EP EP23152543.7A patent/EP4220360B1/en active Active
- 2016-11-11 MX MX2018004978A patent/MX2018004978A/es unknown
- 2016-11-11 CN CN201680066253.6A patent/CN108291226B/zh active Active
- 2016-11-11 JP JP2018521350A patent/JP2018533362A/ja active Pending
- 2016-11-11 CR CR20180264A patent/CR20180264A/es unknown
- 2016-11-11 EP EP16797824.6A patent/EP3374498A1/en active Pending
- 2016-11-14 US US15/351,113 patent/US10494633B2/en active Active
2018
- 2018-04-03 IL IL258488A patent/IL258488B/en active IP Right Grant
- 2018-04-16 ZA ZA2018/02494A patent/ZA201802494B/en unknown
- 2018-04-23 MX MX2022016376A patent/MX2022016376A/es unknown
- 2018-04-23 MX MX2022016377A patent/MX2022016377A/es unknown
- 2018-04-23 MX MX2022016381A patent/MX2022016381A/es unknown
- 2018-04-26 CO CONC2018/0004550A patent/CO2018004550A2/es unknown
- 2018-05-03 CL CL2018001189A patent/CL2018001189A1/es unknown
- 2018-05-08 PH PH12018501005A patent/PH12018501005A1/en unknown
- 2018-05-11 US US15/977,970 patent/US20190154664A1/en active Pending
- 2018-05-11 US US15/977,895 patent/US20190144824A1/en active Pending
- 2018-10-02 HK HK18112618.7A patent/HK1253325A1/zh unknown
2019
- 2019-01-15 HK HK19100676.0A patent/HK1258309A1/zh unknown
- 2019-01-15 HK HK19100670.6A patent/HK1258434A1/zh unknown
- 2019-04-18 US US16/388,714 patent/US10739332B2/en active Active
- 2019-10-24 US US16/663,024 patent/US10718753B2/en active Active
2020
- 2020-04-02 CL CL2020000889A patent/CL2020000889A1/es unknown
- 2020-05-29 AU AU2020203573A patent/AU2020203573B2/en active Active
- 2020-07-20 US US16/933,445 patent/US11320421B2/en active Active
- 2020-08-12 JP JP2020136397A patent/JP7279000B2/ja active Active
2021
- 2021-02-09 HR HRP20210227TT patent/HRP20210227T1/hr unknown
- 2021-07-08 JP JP2021113496A patent/JP2021191262A/ja active Pending
- 2021-08-13 CL CL2021002159A patent/CL2021002159A1/es unknown
2022
- 2022-01-21 US US17/581,089 patent/US11852627B2/en active Active
- 2022-08-05 AU AU2022211910A patent/AU2022211910B2/en active Active
2023
- 2023-01-25 AU AU2023200410A patent/AU2023200410A1/en active Pending
- 2023-01-25 JP JP2023009553A patent/JP2023052630A/ja active Pending
- 2023-02-22 US US18/172,707 patent/US20230296587A1/en active Pending
- 2023-10-20 US US18/491,513 patent/US20240085402A1/en active Pending

Also Published As

Publication number	Publication date
MX2018004978A (es)	2018-07-06
WO2017081250A1 (en)	2017-05-18
EP4220360A2 (en)	2023-08-02
EP3798307A1 (en)	2021-03-31
US11852627B2 (en)	2023-12-26
US20170191064A1 (en)	2017-07-06
US20230296587A1 (en)	2023-09-21
JP2021003113A (ja)	2021-01-14
WO2017081223A1 (en)	2017-05-18
HRP20210227T1 (hr)	2021-03-19
WO2017081254A1 (en)	2017-05-18
US20200057052A1 (en)	2020-02-20
EP3374509A1 (en)	2018-09-19
RU2742007C2 (ru)	2021-02-01
AU2022211910B2 (en)	2024-06-13
CN108350432A (zh)	2018-07-31
IL258488A (en)	2018-05-31
IL281211A (en)	2021-04-29
JP2018533954A (ja)	2018-11-22
CL2021002159A1 (es)	2022-03-11
AU2016352836A1 (en)	2018-04-26
AU2020203573B2 (en)	2022-07-07
IL300119A (en)	2023-03-01
BR112018007633A2 (pt)	2018-11-06
JP7279000B2 (ja)	2023-05-22
AU2016352836B2 (en)	2020-06-25
JP6751142B2 (ja)	2020-09-02
JP7066609B2 (ja)	2022-05-13
MX2022016381A (es)	2023-01-30
HK1258309A1 (zh)	2019-11-08
CR20220077A (es)	2023-04-11
EP3374499A1 (en)	2018-09-19
CN116064540A (zh)	2023-05-05
MX2022016377A (es)	2023-01-30
IL258488B (en)	2021-03-25
US20190154664A1 (en)	2019-05-23
RU2018119315A3 (sr)	2020-03-26
SI3374509T1 (sl)	2021-04-30
US10739332B2 (en)	2020-08-11
HK1258434A1 (zh)	2019-11-08
AU2022211910A1 (en)	2022-11-10
US11320421B2 (en)	2022-05-03
US20190144824A1 (en)	2019-05-16
RU2018119315A (ru)	2019-12-13
KR20230008233A (ko)	2023-01-13
ES2852998T3 (es)	2021-09-14
ZA201802494B (en)	2024-01-31
JP2023052630A (ja)	2023-04-11
IL281211B1 (en)	2023-09-01
CA3004799C (en)	2024-05-14
LT3374509T (lt)	2021-03-10
SG11201803951QA (en)	2018-06-28
US20190310244A1 (en)	2019-10-10
UA125963C2 (uk)	2022-07-20
CO2018004550A2 (es)	2018-11-22
US20200348286A1 (en)	2020-11-05
PE20210451A1 (es)	2021-03-08
HK1253325A1 (zh)	2019-06-14
EP4220360B1 (en)	2024-06-26
US20240085402A1 (en)	2024-03-14
JP2021191262A (ja)	2021-12-16
EP3374498A1 (en)	2018-09-19
PL3374509T3 (pl)	2021-05-04
JP2018533362A (ja)	2018-11-15
CL2020000889A1 (es)	2020-08-28
CL2018001189A1 (es)	2018-08-31
KR20200137027A (ko)	2020-12-08
CR20200118A (es)	2021-04-21
ES2852998T4 (es)	2024-04-25
CN108291226B (zh)	2022-11-04
KR102185465B1 (ko)	2020-12-03
JP2019500851A (ja)	2019-01-17
AU2020203573A1 (en)	2020-06-18
DK3374509T3 (da)	2021-02-15
IL281211B2 (en)	2024-01-01
MX2022016376A (es)	2023-01-30
HUE053197T2 (hu)	2021-06-28
US10494633B2 (en)	2019-12-03
CR20180264A (es)	2018-08-06
US20220146496A1 (en)	2022-05-12
RS61529B1 (sr)	2021-04-29
AU2023200410A1 (en)	2023-02-23
CN116064539A (zh)	2023-05-05
US10718753B2 (en)	2020-07-21
CA3004799A1 (en)	2017-05-18
EP4220360A3 (en)	2023-08-23
CN108350431A (zh)	2018-07-31
KR102482440B1 (ko)	2022-12-29
PH12018501005A1 (en)	2019-01-28
EP3374509B1 (en)	2020-12-16
NZ741585A (en)	2024-01-26
PE20181157A1 (es)	2018-07-19
KR20180070611A (ko)	2018-06-26
CN108291226A (zh)	2018-07-17

Publication	Publication Date	Title
IL281211B1 (en)	2023-09-01	Oligonucleotides to induce paternal ube3a expression
IL256634A (en)	2018-02-28	Therapeutic oligonucleotides
IL256063A (en)	2018-01-31	Autoinjector
IL257091B (en)	2022-06-01	Targeted oligonucleotides
GB201520271D0 (en)	2015-12-30	Dispenser
GB201520997D0 (en)	2016-01-13	Dispensers
GB201503408D0 (en)	2015-04-15	Oligonucleotides
GB201518910D0 (en)	2015-12-09	Dispensers
HK1243655A1 (zh)	2018-07-20	除菌片
GB201510597D0 (en)	2015-07-29	Event generating unit
GB201504124D0 (en)	2015-04-22	Oligonucleotides
IL257008A (en)	2018-03-29	Multi-chemistry dispenser
GB201506153D0 (en)	2015-05-27	Dispenser Apparatus
HK1245714A1 (zh)	2018-08-31	分配器
PL3329004T3 (pl)	2020-10-05	Terapeutyczne oligonukleotydy
GB2539870B (en)	2021-01-06	Dispenser
SG11201700652PA (en)	2017-02-27	Modified antimir-138 oligonucleotides
GB2535448B (en)	2020-11-25	Dispenser
PL3056117T3 (pl)	2019-10-31	Urządzenie sprzedażowe
PL3377148T3 (pl)	2021-12-13	Autostrzykawka
SG10202108834TA (en)	2021-09-29	Emulsions
HK1243793A1 (zh)	2018-07-20	虛擬化感知預取
GB201610677D0 (en)	2016-08-03	Relocation unit
PT3374509T (pt)	2021-02-15	Oligonucleótidos para induzir a expressão paterna de ube3a
GB2555225B (en)	2020-12-09	Hydrocarbon-contamination treatment unit